Investigation Announced for EyePoint, Inc. After Disappointing Trial Results: A Call to Investors

EyePoint, Inc. Investigation Launched

In an alarming development for investors, Kessler Topaz Meltzer & Check, LLP (KTMC) has announced an investigation into EyePoint, Inc. (NASDAQ: EYPT). The renowned law firm is probing possible violations of federal securities laws pertaining to the company's disclosures, which may have significant repercussions for shareholders who invested in EyePoint securities. This comes after significant financial losses reported by many individuals who purchased EyePoint’s shares.

Disappointing Clinical Trial Results

On August 17, 2026, EyePoint released press information regarding the pivotal Phase 3 clinical trial results for its experimental treatment, DURAVYU™. The announcement stated that the treatment, designed for wet age-related macular degeneration (wet AMD), failed to achieve its primary endpoint in the clinical trials. Specifically, it did not demonstrate superior changes in best-corrected visual acuity compared to the on-label alternative, aflibercept, when analyzed in the complete dataset of the Phase 3 LUGANO trial.

This disappointing update caused EyePoint’s stock to plummet by over 66%, raising serious questions regarding the efficacy of DURAVYU and the company's future prospects. This stark decline in stock value illustrates the immediate impact of the clinical trial failure on investor confidence and financial stability.

Legal Rights for Affected Investors

The fallout of this significant stock drop has led to a growing concern among investors who may have been misled regarding the performance and potential of EyePoint's products. Investors who acquired EyePoint, Inc. shares and encountered substantial losses following the disappointing trial results are encouraged to seek legal counsel. KTMC has reached out to affected individuals, urging them to consider their rights under federal securities laws.

Should any investors recognize that they have experienced losses associated with their investments in EyePoint, the law firm offers the opportunity for these individuals to discuss their cases without obligation. The aim is to provide legal options for those wishing to pursue potential claims against EyePoint, Inc.

KTMC: A Leader in Securities Litigation

Kessler Topaz Meltzer & Check, LLP is well-regarded as a plaintiff-focused law firm that specializes in securities fraud class actions and safeguarding global investors. With a history of achieving significant recoveries for its clients, the firm has been acknowledged for its exemplary legal practice and has been consistently ranked as one of the top firms within the securities litigation field.

With offices in Pennsylvania and California, KTMC has successfully recovered over $25 billion for its clients over the years. The law firm's reputation for protecting investor rights speaks to its commitment and capability to handle complex securities issues. By representing both individual investors and major institutions, KTMC aims to uphold accountability within the market and provide justice for those impacted by fraudulent activities.

Next Steps for Investors

If you have purchased or acquired securities of EyePoint, Inc. and have suffered financial losses, it would be prudent to reach out to Kessler Topaz Meltzer & Check for a consultation regarding your case. The firm’s experienced attorneys stand ready to assess your circumstances and discuss potential actions to protect your interests. To begin the discussion, investors can submit their details directly via the KTMC website.

Investors should not overlook this opportunity, as the consequences of the failed clinical trials for EyePoint may continue to impact shareholder value dramatically. It’s essential to stay informed about developments and legal avenues available following such unforeseen circumstances within the healthcare sector.